Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
Hengrui Pharma has agreed with US-based Braveheart Bio, which specialises in cardiovascular diseases, granting it an exclusive licence for its…
Novartis has secured a licensing agreement with China-based Argo Biopharma just after signing a contract with Arrowhead, marking two small…
Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli…
A trial investigating the ability of Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met its…
Merck has agreed to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn. The acquisition will be made…
Medera and its subsidiary Novoheart have collaborated with scientists at the University of California San Diego School of Medicine and…
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for…
CirCode Biomed’s circular RNA drug HM2002 has received investigational new drug (IND) clearance from the US Food and Drug Administration…
HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral cardiovascular medicines, Nexletol (bempedoic acid)…